{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-034128","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.463733+00:00","generated_at":"2026-06-03T18:41:09.670843+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OptimizeRx Q4 revenue $28.4M (+44% YoY), non-GAAP net income $4.6M, reiterates 2024 guidance of $100M revenue","bullets":["Q4 revenue $28.4M (+44% YoY); gross profit $17.8M (63% margin).","GAAP net loss $4.1M ($0.23/share); non-GAAP net income $4.6M ($0.26/share).","Full year revenue $71.5M (+15%); GAAP net loss $17.6M; non-GAAP net income $4.4M.","Adjusted EBITDA Q4 $5.8M (+50% YoY); full year $3.6M.","Reiterates FY2024 guidance: revenue ≥$100M, Adjusted EBITDA ≥$11M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-034128","json":"https://secwatch.observer/filing/0001213900-24-034128.json","markdown":"https://secwatch.observer/filing/0001213900-24-034128.md","text":"https://secwatch.observer/filing/0001213900-24-034128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/0001213900-24-034128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/ea0204128-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T18:41:09.670843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a4192f19853c91b3489e68a38e78ef1021851df","claim":"OptimizeRx Corp reported the full year ended December 31, 2023 results: revenue $71.5 million, net income $(17.6) million, EPS $(1.03) per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"cial Highlights ● Revenue in the fourth quarter of 2023 increased 44% to $28.4 million, from $19.7 million in the same period of 2022, with the full year revenue coming in at $71.5 million, a 15% increase when compared to the same year-ago period. ● Gross profit in the fourth quarter of 2023 increased 43% year-over-year to $17.8 million. Gross profit for the full","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/0001213900-24-034128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$71.5 million"},{"label":"Net income","value":"$(17.6) million"},{"label":"EPS","value":"$(1.03) per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"609c84d5958741529031e84d9939f46ef45d4548","claim":"OptimizeRx Corp reported the fourth quarter ended December 31, 2023 results: revenue $28.4 million, net income $(4.1) million, EPS $(0.23) per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"Revenue in the fourth quarter of 2023 increased 44% to $28.4 million, from $19.7 million in the same period of 2022, with the full year revenue coming in at $71.5 million, a 15% increase when compared to the same year-ago period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390024034128/0001213900-24-034128-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$28.4 million"},{"label":"Net income","value":"$(4.1) million"},{"label":"EPS","value":"$(0.23) per basic and diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}